TY - JOUR
T1 - Tricuspid Regurgitation
T2 - From Imaging to Clinical Trials to Resolving the Unmet Need for Treatment
AU - Grapsa, Julia
AU - Praz, Fabien
AU - Sorajja, Paul
AU - Cavalcante, Joao L.
AU - Sitges, Marta
AU - Taramasso, Maurizio
AU - Piazza, Nicolo
AU - Messika-Zeitoun, David
AU - Michelena, Hector I.
AU - Hamid, Nadira
AU - Dreyfus, Julien
AU - Benfari, Giovanni
AU - Argulian, Edgar
AU - Chieffo, Alaide
AU - Tchetche, Didier
AU - Rudski, Lawrence
AU - Bax, Jeroen J.
AU - Stephan von Bardeleben, Ralph
AU - Patterson, Tiffany
AU - Redwood, Simon
AU - Bapat, Vinayak N.
AU - Nickenig, Georg
AU - Lurz, Philipp
AU - Hausleiter, Jörg
AU - Kodali, Susheel
AU - Hahn, Rebecca T.
AU - Maisano, Francesco
AU - Enriquez-Sarano, Maurice
N1 - Publisher Copyright:
© 2024 American College of Cardiology Foundation
PY - 2024/1
Y1 - 2024/1
N2 - Tricuspid regurgitation (TR) is a highly prevalent and heterogeneous valvular disease, independently associated with excess mortality and high morbidity in all clinical contexts. TR is profoundly undertreated by surgery and is often discovered late in patients presenting with right-sided heart failure. To address the issue of undertreatment and poor clinical outcomes without intervention, numerous structural tricuspid interventional devices have been and are in development, a challenging process due to the unique anatomic and physiological characteristics of the tricuspid valve, and warranting well-designed clinical trials. The path from routine practice TR detection to appropriate TR evaluation, to conduction of clinical trials, to enriched therapeutic possibilities for improving TR access to treatment and outcomes in routine practice is complex. Therefore, this paper summarizes the key points and methods crucial to TR detection, quantitation, categorization, risk-scoring, intervention-monitoring, and outcomes evaluation, particularly of right-sided function, and to clinical trial development and conduct, for both interventional and surgical groups.
AB - Tricuspid regurgitation (TR) is a highly prevalent and heterogeneous valvular disease, independently associated with excess mortality and high morbidity in all clinical contexts. TR is profoundly undertreated by surgery and is often discovered late in patients presenting with right-sided heart failure. To address the issue of undertreatment and poor clinical outcomes without intervention, numerous structural tricuspid interventional devices have been and are in development, a challenging process due to the unique anatomic and physiological characteristics of the tricuspid valve, and warranting well-designed clinical trials. The path from routine practice TR detection to appropriate TR evaluation, to conduction of clinical trials, to enriched therapeutic possibilities for improving TR access to treatment and outcomes in routine practice is complex. Therefore, this paper summarizes the key points and methods crucial to TR detection, quantitation, categorization, risk-scoring, intervention-monitoring, and outcomes evaluation, particularly of right-sided function, and to clinical trial development and conduct, for both interventional and surgical groups.
KW - clinical trials
KW - endpoints
KW - multimodality imaging
KW - structural interventions
KW - tricuspid valve
UR - http://www.scopus.com/inward/record.url?scp=85174354874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85174354874&partnerID=8YFLogxK
U2 - 10.1016/j.jcmg.2023.08.013
DO - 10.1016/j.jcmg.2023.08.013
M3 - Review article
C2 - 37731368
AN - SCOPUS:85174354874
SN - 1936-878X
VL - 17
SP - 79
EP - 95
JO - JACC: Cardiovascular Imaging
JF - JACC: Cardiovascular Imaging
IS - 1
ER -